Medication treatment of different types of alcoholism
Open accessAbstract
Alcoholism remains a serious cause of morbidity and mortality despite progress through neurobiological research in identifying new pharmacological strategies for its treatment. Drugs that affect neural pathways that modulate the activity of the cortico-mesolimbic dopamine system have been shown to alter drinking behavior, presumably because this dopaminergic system is closely associated with rewarding behavior. Ondansetron, naltrexone, topiramate, and baclofen are examples. Subtyping alcoholism in adults into an early-onset type, with chronic symptoms and a strong biological predisposition to the disease, and a late-onset type, typically brought on by psychosocial triggers and associated with mood symptoms, may help in the selection of optimal therapy. Emerging adults with binge drinking patterns also might be aided by selective treatments. Although preliminary work on the pharmacogenetics of alcoholism and its treatment has been promising, the assignment to treatment still depends on clinical assessment. Brief behavioral interventions that encourage the patient to set goals for a reduction in heavy drinking or abstinence also are part of optimal therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The psychological or cognitive threat of a DER is thought to be dominant and active and thus dissuade use.
“To prevent the first drink, however, the psychological or cognitive threat is thought to be dominant and active and thus dissuade use [5], [6], [7].”
From Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis (2014) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 1× · see citing works
“Alcohol dependence often follows a chronic, relapsing course (2) similar to other medical disorders, such as diabetes.”
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221 · see citing works
Neurogenetic Adaptive Mechanisms in Alcoholism
Cloninger, C. R. (1987) · Science · doi:10.1126/science.2882604 · Cited by 2,203 · cited 1× · see citing works
“(9), there are at least two different subtypes of alcoholism.”
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930 · see citing works
Self-citationHasin, D. S., Goodwin, R. D., Stinson, F. S., & Grant, B. F. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.10.1097 · Cited by 1,645 · see citing works
Finite Mixture Modeling with Mixture Outcomes Using the EM Algorithm
Muthén, B., & Shedden, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00463.x · Cited by 1,498 · cited 1× · see citing works
“Those who drink severely or binge drink between the ages of 18 and 24 are more likely to progress to alcohol abuse or dependence diagnoses (29, 30).”
Wechsler, H., Lee, J. E., Kuo, M., Seibring, M., Nelson, T. F., & Lee, H. (2002) · Journal of American College Health · doi:10.1080/07448480209595713 · Cited by 1,457 · cited 4× · see citing works
“One-fourth of college students report drinking-related academic problems, such as missing classes, falling behind, performing poorly on examinations and papers, and getting lower grades (19, 26, 27).”
InfluentialVolume, I. I. (2017) · Institute for Social Research eBooks · doi:10.3998/2027.42/139710 · Cited by 1,369 · see citing works
The Alcohol Use Disorders Identification Test (AUDIT): A review of recent research
Reinert, D. F., & Allen, J. P. (2002) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02534.x · Cited by 1,143 · see citing works
Hingson, R., Heeren, T., Winter, M., & Wechsler, H. (2005) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.26.021304.144652 · Cited by 1,102 · see citing works
Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction
Koob, G. F., & Le Moal, M. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1442 · Cited by 963 · see citing works
Babor, T. F. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080007002 · Cited by 903 · see citing works
Magnitude of alcohol-related mortality and morbidity among U.S. college students ages 18-24.
Hingson, R., Heeren, T., Zakocs, R. C., Kopstein, A. N., & Wechsler, H. (2002) · Journal of Studies on Alcohol · doi:10.15288/jsa.2002.63.136 · Cited by 846 · see citing works
Shank, R. P., Gardocki, J. F., Streeter, A. J., & Maryanoff, B. E. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb02163.x · Cited by 810 · see citing works
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743 · see citing works
Self-citationAlcohol abuse and dependence among U.S. college students.
Knight, J. R., Wechsler, H., Kuo, M., Seibring, M., Weitzman, E. R., & Schuckit, M. A. (2002) · Journal of Studies on Alcohol · doi:10.15288/jsa.2002.63.263 · Cited by 687 · see citing works
Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D’Angelo, C., Caputo, F., Zambon, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61814-5 · Cited by 683 · see citing works
Brief Alcohol Screening and Intervention for College Students (Basics): A Harm Reduction Approach
Kivlahan, D. R., Dimeff, L. A., Baer, J. S., & Marlatt, G. A. (1999) · Cited by 643 · see citing works
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571 · see citing works
Alcohol Use Disorders Among US College Students and Their Non–College-Attending Peers
Slutske, W. S. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.3.321 · Cited by 544 · see citing works
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542 · see citing works
Self-citationBrief intervention for heavy-drinking college students: 4-year follow-up and natural history.
Baer, J. S., Kivlahan, D., Blume, A. W., McKnight, P., & Marlatt, G. (2001) · American Journal of Public Health · doi:10.2105/ajph.91.8.1310 · Cited by 525 · see citing works
Dawson, D. A., Grant, B. F., Stinson, F. S., & Chou, P. S. (2004) · Journal of Studies on Alcohol · doi:10.15288/jsa.2004.65.477 · Cited by 462 · see citing works
The Alcohol Use Disorders Identification Test (AUDIT) in a College Sample
Fleming, M. F., Barry, K. L., & Macdonald, R. (1991) · International Journal of the Addictions · doi:10.3109/10826089109062153 · Cited by 458 · cited 1× · see citing works
“The National Institute on Alcohol Abuse and Alcoholism Clinician’s Guide (49) recommends that a first step in wanted or unprotected sex, sexually transmitted diseases, pregnancy, blackouts, and missed classes (22, 23).”
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · see citing works
Jennison, K. M. (2004) · The American Journal of Drug and Alcohol Abuse · doi:10.1081/ada-200032331 · Cited by 401 · see citing works
Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism
Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kämpf, P., Stracke, R., Baehr, M., Naber, D., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.92 · Cited by 400 · see citing works
Hemphill, S. A., WHITE, H. R., Chung, I., Hawkins, J. D., & Catalano, R. F. (2000) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2000.tb02071.x · Cited by 390 · cited 1× · see citing works
“Those who drink severely or binge drink between the ages of 18 and 24 are more likely to progress to alcohol abuse or dependence diagnoses (29, 30).”
Bi-directional effects of GABAB receptor agonists on the mesolimbic dopamine system
Cruz, H. G., Ivanova, T., Lunn, M.-L., Stoffel, M., Slesinger, P. A., & Lüscher, C. (2004) · Nature Neuroscience · doi:10.1038/nn1181 · Cited by 367 · see citing works
Fluoxetine in Depressed Alcoholics
Cornelius, J. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200024004 · Cited by 356 · see citing works
Blazer, D. G., & Wu, L.-T. T. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09010016 · Cited by 322 · see citing works
White, H. S., Brown, S. D., Woodhead, J. H., Skeen, G. A., & Wolf, H. H. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb02165.x · Cited by 300 · see citing works
Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 265 · see citing works
Self-citationDrug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255 · cited 1× · see citing works
“Without a pharmacological adjunct to psychosocial therapy, the clinical outcome is poor, with up to 70% of patients resuming drinking within 1 year (3, 4).”
Patterns of DSM-IV alcohol abuse and dependence symptoms in adolescent drinkers.
Martin, C. S., Kaczynski, N. A., Maisto, S. A., Bukstein, O., & Moss, H. B. (1995) · Journal of Studies on Alcohol · doi:10.15288/jsa.1995.56.672 · Cited by 214 · see citing works
Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism
George, D. T., Gilman, J. M., Hersh, J., Thorsell, A., Herion, D. W., Geyer, C., Peng, X., Kielbasa, W., Rawlings, R. R., Brandt, J., et al. (2008) · Science · doi:10.1126/science.1153813 · Cited by 213 · see citing works
The human serotonin transporter gene polymorphism-basic research and clinical implications
Heils, A., M��ner, R., & Lesch, K. (1997) · Journal of Neural Transmission · doi:10.1007/bf01273314 · Cited by 209 · see citing works
Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam
Addolorato, G., Leggio, L., Abenavoli, L., Agabio, R., Caputo, F., Capristo, E., Colombo, G., Gessa, G. L., & Gasbarrini, G. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.042 · Cited by 203 · see citing works
Gelernter, J. E., Gueorguieva, R. V., Kranzler, H. R., Zhang, H., Cramer, J. A., Rosenheck, R. A., Krystal, J. H., & the VA Cooperative Study #425 Study Group (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00339.x · Cited by 201 · see citing works
Comorbidity for Alcoholism and Depression
Merikangas, K. R., & Gelernter, C. S. (1990) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30339-3 · Cited by 197 · see citing works
Finney, J. W., HAHN, A. C., & Moos, R. H. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911217733.x · Cited by 188 · cited 1× · see citing works
“Without a pharmacological adjunct to psychosocial therapy, the clinical outcome is poor, with up to 70% of patients resuming drinking within 1 year (3, 4).”
Types of alcoholics: concurrent and predictive validity of some common classification schemes
Babor, T. F., Dolinsky, Z. S., Meyer, R. E., Hesselbrock, M. N., HOFMANN, M., & Tennen, H. A. (1992) · British Journal of Addiction · doi:10.1111/j.1360-0443.1992.tb01921.x · Cited by 182 · see citing works
Brower, K. J., Kim, H. M., Strobbe, S., Karam‐Hage, M., Consens, F. B., & Zucker, R. A. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00706.x · Cited by 180 · see citing works
SUBTYPES OF ALCOHOLISM AND THEIR ROLE IN THERAPY
LESCH, O. M., & WALTER, H. (1996) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a008221 · Cited by 164 · cited 1× · see citing works
“For example, some researchers have proposed more elaborate classification schemes, with up to four subtypes that might respond differentially to particular therapeutic agents (15, 16).”
O'Neill, S. E., Parra, G. R., & Sher, K. J. (2001) · Psychology of Addictive Behaviors · doi:10.1037//0893-164x.15.4.350 · Cited by 158 · see citing works
Calculating standard drink units: international comparisons
Miller, W. R., Heather, N., & Hall, W. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb02627.x · Cited by 156 · see citing works
HIV-risk behaviours of American spring break vacationers: a case of situational disinhibition?
Apostolopoulos, Y., Sönmez, S., & Yu, C. H. (2002) · International Journal of STD & AIDS · doi:10.1258/095646202320753673 · Cited by 144 · cited 1× · see citing works
“The risk for sexually transmitted diseases as a result of multiple sex partners and unprotected sex is elevated during periods such as spring break, when casual sex, impulsivity, and reduced availability of condoms are compounded with increased use of, or bingeing on, alcohol or drugs (25).”
Recent Advances in the Development of Treatments for Alcohol and Cocaine Dependence
Johnson, B. A. (2005) · CNS Drugs · doi:10.2165/00023210-200519100-00005 · Cited by 133 · see citing works
Self-citationThe comorbidity of alcohol dependence and affective disorders: treatment implications
Lynskey, M. T. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00095-7 · Cited by 133 · see citing works
Johnson, B. A. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.11.1188 · Cited by 125 · see citing works
Self-citationHarris, B. R., Prendergast, M., Gibson, D. A., Rogers, D. T., Blanchard, J. A., Holley, R. C., Fu, M. C., Hart, S. R., Pedigo, N. W., & Littleton, J. M. (2002) · PubMed · doi:10.1097/01.alc.0000042011.99580.98 · Cited by 124 · see citing works
Presley, C. A., & Pimentel, E. R. (2006) · Journal of Studies on Alcohol · doi:10.15288/jsa.2006.67.324 · Cited by 123 · cited 1× · see citing works
“Alcohol-related consequences are more likely among students classified as hazardous drinkers than among those classified as nonhazardous drinkers (28).”
A failed norms social marketing campaign.
Clapp, J. D., Lange, J. E., Russell, C., Shillington, A., & Voas, R. B. (2003) · Journal of Studies on Alcohol · doi:10.15288/jsa.2003.64.409 · Cited by 113 · cited 1× · see citing works
“Binge drinking remains frequent among college students despite increased prevention efforts over the past decade (18, 19).”
Harris, B. R., Prendergast, M., Gibson, D. A., Rogers, D. T., Blanchard, J. A., Holley, R. C., Fu, M. C., Hart, S. R., Pedigo, N. W., & Littleton, J. M. (2002) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02484.x · Cited by 111 · see citing works
HIGH PREVALENCE, PERSISTENT HAZARDOUS DRINKING AMONG NEW ZEALAND TERTIARY STUDENTS
Kypri, K. (2002) · Alcohol and Alcoholism · doi:10.1093/alcalc/37.5.457 · Cited by 109 · cited 1× · see citing works
“The National Institute on Alcohol Abuse and Alcoholism Clinician’s Guide (49) recommends that a first step in wanted or unprotected sex, sexually transmitted diseases, pregnancy, blackouts, and missed classes (22, 23).”
O'Neill, S. E., Parra, G. R., & Sher, K. J. (2001) · Psychology of Addictive Behaviors · doi:10.1037/0893-164x.15.4.350 · Cited by 109 · see citing works
An evaluation of Type A and B alcoholics
Schuckit, M. A., TIPP, J. E., Smith, T. L., SHAPIRO, E., HESSELBROCK, V. M., Bucholz, K. K., Reich, T., & Nürnberger, J. I. (1995) · Addiction · doi:10.1046/j.1360-0443.1995.90911894.x · Cited by 108 · see citing works
Anton, R. F., Kranzler, H. R., Breder, C. D., Marcus, R. N., Carson, W. H., & Han, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181602fd4 · Cited by 106 · see citing works
Finney, J. W., HAHN, A. C., & Moos, R. H. (1996) · Addiction · doi:10.1111/j.1360-0443.1996.tb03801.x · Cited by 105 · see citing works
Use and misuse of alcohol among older women.
Blow, F. C., & Barry, K. L. (2002) · Europe PMC (PubMed Central) · Cited by 104 · see citing works
Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking
Krishnan‐Sarin, S., Krystal, J. H., Shi, J. M., Pittman, B. P., & O’Malley, S. S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.018 · Cited by 102 · see citing works
The course of alcoholism. Long-term prognosis in different types
Lesch, O., Dietzel, M., Musalek, M., Walter, H., & Zeiler, K. J. (1988) · Forensic Science International · doi:10.1016/0379-0738(88)90225-3 · Cited by 98 · cited 1× · see citing works
“For example, some researchers have proposed more elaborate classification schemes, with up to four subtypes that might respond differentially to particular therapeutic agents (15, 16).”
Comorbid alcoholism and depression: treatment issues.
Thase, M. E., Salloum, I. M., & Cornelius, J. (2001) · PubMed · Cited by 95 · see citing works
Serotonergic Agents and Alcoholism Treatment: Rebirth of the Subtype Concept???An Hypothesis
Johnson, B. A. (2000) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2000.tb04581.x · Cited by 83 · cited 2× · see citing works
“In the future, more contemporary and accurate alcoholism subtype classification schemes that predominantly employ molecular genetic markers, with or without additional epidemiological or psychosocial determinants, may be more predictive of drinking outcomes and therapeutic response to medications (14).”
Self-citationAit‐Daoud, N., Malcolm, R. J., & Johnson, B. A. (2006) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.12.029 · Cited by 80 · see citing works
Self-citationAn evaluation of Type A and B alcoholics
Schuckit, M. A., TIPP, J. E., Smith, T. L., SHAPIRO, E., HESSELBROCK, V. M., Bucholz, K. K., Reich, T., & Nürnberger, J. I. (1995) · Addiction · doi:10.1111/j.1360-0443.1995.tb01089.x · Cited by 75 · see citing works
Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers
Arias, A. J., Armeli, S., Gelernter, J. E., Covault, J., Kallio, A., Karhuvaara, S., Koivisto, T., Mäkelä, R., & Kranzler, H. R. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00735.x · Cited by 70 · see citing works
Kenna, G. A., Zywiak, W. H., McGeary, J. E., Leggio, L., McGeary, C., Wang, S. V., Grenga, A. M., & Swift, R. M. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00835.x · Cited by 47 · see citing works
McEachin, R. C., Keller, B. J., Saunders, E. F. H., & McInnis, M. G. (2008) · BioData Mining · doi:10.1186/1756-0381-1-2 · Cited by 45 · see citing works
Wang, J., & el‐Guebaly, N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900106 · Cited by 44 · see citing works
Adolescents and Illicit Drug Use
Bruner, A. B. (1998) · JAMA · doi:10.1001/jama.280.7.597 · Cited by 43 · cited 1× · see citing works
“Short-term problems associated with drug and alcohol use in emerging adulthood include violence, depression, and unprotected sex (19, 24).”
Sturtevant, J. (1999) · PubMed · Cited by 41 · see citing works
Can Serotonin Transporter Genotype Predict Craving in Alcoholism?
Ait‐Daoud, N., Roache, J. D., Dawes, M. A., Liu, L., Wang, X., Javors, M. A., Seneviratne, C., & Johnson, B. A. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00962.x · Cited by 33 · see citing works
Self-citationJohnson, B. A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1547 · Cited by 20 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 9
- [5]Johnson BA DiClemente CC Ait-Daoud N Stoks SM Johnson BA Ruiz P Galanter M Brief Behavioral Compliance Enhancement Treatment (BBCET) manual, in Handbook of clinical alcoholism treatment 2003 282 301 Lippincott Williams & Wilkins Baltimore, MD
- [8]American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000 American Psychiatric Association Washington, D.C. 4th edition text revision
- [45]Hemby SE Johnson BA Dworkin SI Johnson BA Roache JD Neurobiological basis of drug reinforcement, in Drug addiction and its treatment: nexus of neuroscience and behavior 1997 137 169 Lippincott-Raven Philadelphia
- [49]National Institute on Alcohol Abuse and Alcoholism Helping patients who drink too much: a clinician's guide, updated 2005 edition 2005 U.S. Department of Health and Human Services Bethesda, MD NIH Publication No. 07-3769
- [54]Johnson BA Rosenthal N Capece JA Wiegand F Mao L Beyers K McKay A Ait-Daoud N Anton RF Ciraulo DA Kranzler HR Mann K O'Malley SS Swift RM Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group Topiramate for treating alcohol dependence: a randomized controlled trial JAMA 2007 298 1641 1651 17925516
- [57]Johnson BA Rosenthal N Capece JA Wiegand F Mao L Beyers K McKay A Ait-Daoud N Addolorato G Anton RF Ciraulo DA Kranzler HR Mann K O'Malley SS Swift RM Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment Arch Intern Med 2008 168 1188 1199 18541827
- [58]Cruz HG Ivanova T Lunn ML Stoffel M Slesinger PA Lüscher C Bidirectional effects of GABA(B) receptor agonists on the mesolimbic dopamine system Nat Neurosci 2004 7 153 159 14745451
- [61]New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) Alpha-baclofen 1999 Data sheet, http://www.medsafe.govt.nz/profs/datasheet/a/alphabaclofentab.htm 10561993
- [68]Ait-Daoud N Johnson BA Johnson BA Ruiz P Galanter M Medications for the treatment of alcoholism, in Handbook of clinical alcoholism treatment 2003 119 130 Lippincott Williams & Wilkins Baltimore, MD
Cited by
Sorted by citations
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.004 · Cited by 720 · see citing works
“The 5-HT3 antagonist ondansetron has been shown to reduce drinking, but this effect was limited to ‘early onset’ alcoholics [59].”
BackgroundConnor, J. P., Haber, P. S., & Hall, W. D. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00122-1 · Cited by 389 · see citing works
Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347 · see citing works
“Its mechanism of action for maintaining alcohol abstinence is thought to be primarily psychological [4,5,6,7] and based on a highly disagreeable pharmacological effect if alcohol is consumed.”
BackgroundLingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332 · see citing works
“Finally, the 5HT3 antagonist, ondansetron, has shown promise, particularly in early onset alcoholism (Johnson, 2010).”
BackgroundLeclercq, S., Cani, P. D., Neyrinck, A. M., Stärkel, P., Jamar, F., Mikolajczak, M., Delzenne, N. M., & de Timary, P. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.04.001 · Cited by 310 · see citing works
“Indeed current pharmacological approaches of alcohol-dependence that only target brain neurotransmitters have proved so far to be modestly efficient (Johnson, 2010), eventually because they fail to take into account of intestinal permeability and inflammation as a driving force for the…”
Dihydromyricetin As a Novel Anti-Alcohol Intoxication Medication
Shen, Y., Lindemeyer, A. K., Gonzalez, C., Shao, X. M., Spigelman, I., Olsen, R. W., & Liang, J. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4639-11.2012 · Cited by 213 · see citing works
“, 2005) due to some isoflavone ingredients, like daidzein, puerarin, and genistein (Johnson, 2010), mimicked by a synthetic analog CVT10216 (Arolfo et al.”
Alcohol use disorders in the elderly: A brief overview from epidemiology to treatment options
Caputo, F., Vignoli, T., Leggio, L., Addolorato, G., Zoli, G., & Bernardi, M. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.03.019 · Cited by 168 · see citing works
“Moreover, due to the elderly's predisposition to forgetfulness, some hypotheses have been raised regarding the possible usefulness of the injectable extended-release formulation of naltrexone (380 mg/ month for 4 months) after a period of abstinence of 3–5 days (Johnson, 2010).”
Alcohol use disorders and current pharmacological therapies: the role of GABAA receptors
Liang, J., & Olsen, R. W. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.50 · Cited by 155 · see citing works
Targeting glutamate uptake to treat alcohol use disorders
Rao, P. S. S., Bell, R. L., Engleman, E. A., & Sari, Y. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00144 · Cited by 136 · see citing works
“New Orleans, USA Raman Chandrasekar, Kansas State University, USA Doo-Sup Choi, Mayo Clinic College of Medicine, USA *Correspondence: Richard L. Bell, Department of Psychiatry, Indiana University School of Medicine, Neuroscience Research Building, NB300, 320 W. 15th Street, Indianapolis, IN 46202-2266, USA ribell@iupu…”
BackgroundBell, R. L., Sable, H. J. K., Colombo, G., Hyytiä, P., Rodd, Z. A., & Lumeng, L. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.07.007 · Cited by 119 · see citing works
Fostering multiple healthy lifestyle behaviors for primary prevention of cancer.
Spring, B. J., King, A. C., Pagoto, S., Horn, L. V., & Fisher, J. D. (2015) · American Psychologist · doi:10.1037/a0038806 · Cited by 116 · see citing works
“…outreach (Elbel et al., 2013) Alcohol Contingency Management (NIDA, 2012), Intensive behavioral counseling (Miller, 2009), Pharmacotherapy (B. Johnson, 2010), Technology supported treatment (Rooke et al., 2010) School, family, and multicomponent youth prevention (Tsertsvadze A. Foxcroft DR,…”
BackgroundSarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances
Dasarathy, J., McCullough, A. J., & Dasarathy, S. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13425 · Cited by 111 · see citing works
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript reviews have discussed this approach(Miller et al., 2015, Lee and Leggio, 2014, Johnson, 2010).”
BackgroundPharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107 · see citing works
“The FDA has also approved the use of long-acting injectable naltrexone [5,6].”
BackgroundRat animal models for screening medications to treat alcohol use disorders
Bell, R. L., Hauser, S. R., Liang, T., Sari, Y., Maldonado‐Devincci, A. M., & Rodd, Z. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.02.004 · Cited by 90 · see citing works
“Two examples are the mu-opioid receptor (MOR) variant, OPRM1, and the long and short variants of the serotonin transporter (SERT) (Berretini, 2013; Johnson, 2004, 2010; Johnson et al., 2003).”
BackgroundThe Pharmacogenetics of Alcohol Use Disorder
Jones, J. D., Comer, S. D., & Kranzler, H. R. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12643 · Cited by 79 · see citing works
“Clinical pharmacogenetic studies must also recognize and control for sample heterogeneity (Johnson, 2010; Leggio et al., 2009; Pombo and Lesch, 2009), which has often been ignored in the many published pharmacogenetic studies that represent secondary analyses of medications trials.”
BackgroundMaccioni, P., Zaru, A., Loi, B., Lobina, C., Carai, M. A. M., Gessa, G. L., Capra, A., Mugnaini, C., Pasquini, S., Corelli, F., et al. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01782.x · Cited by 75 · see citing works
Parkitna, J. M. R., Sikora, M., Gołda, S., Gołembiowska, K., Bystrowska, B., Engblom, D., Bilbao, A., & Przewłocki, R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.019 · Cited by 63 · see citing works
Ivermectin reduces alcohol intake and preference in mice
Yardley, M. M., Wyatt, L. R., Khoja, S., Asatryan, L., Ramaker, M. J., Finn, D. A., Alkana, R. L., Huynh, N., Louie, S. G., Petasis, N. A., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.014 · Cited by 62 · see citing works
“As such, development of effective treatments for AUDs represents an important public health goal (Bouchery et al., 2011; Heilig and Egli, 2006; Johnson, 2010; Johnson et al., 2007; Steensland et al., 2007).”
Yardley, M. M., & Ray, L. A. (2016) · Addiction Biology · doi:10.1111/adb.12349 · Cited by 60 · see citing works
“As such, development of effective treatments for AUD represents an important public health goal (Heilig and Egli, 2006; Johnson et al., 2007; Steensland et al., 2007; Johnson, 2010; Bouchery et al., 2011).”
BackgroundLipophagy and Alcohol-Induced Fatty Liver
Li, Y., Yang, C., Thomes, P. G., Kharbanda, K. K., Casey, C. A., McNiven, M. A., & Donohue, T. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00495 · Cited by 60 · see citing works
“Abstinence from alcohol along with proper pharmacological (Johnson, 2010) and behavioral therapies (Hagedorn et al., 2016) can effectively minimize recidivism and reverse steatosis in people with AUDs.”
BackgroundIncreased Alcohol Seeking in Mice Lacking Gpr88 Involves Dysfunctional Mesocorticolimbic Networks
Hamida, S. B., Mendonça-Netto, S., Arefin, T. M., Nasseef, M. T., Boulos, L., McNicholas, M., Ehrlich, A. T., Clarke, E., Moquin, L., Gratton, A. P., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.026 · Cited by 55 · see citing works
Efficacy and Tolerability of Baclofen in Substance Use Disorders: A Systematic Review
Agabio, R., Preti, A., & Gessa, G. L. (2013) · European Addiction Research · doi:10.1159/000347055 · Cited by 56 · see citing works
The 5-HT7 receptor as a potential target for treating drug and alcohol abuse
Hauser, S. R., Hedlund, P. B., Roberts, A. J., Sari, Y., Bell, R. L., & Engleman, E. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00448 · Cited by 56 · see citing works
“Therefore, it has been proposed that modulation of the 5-HT system is a viable therapy for alcoholism in a sub-set of patients, suggesting its role in pharmacogenetics (Johnson, 2004, 2010; Wrase et al., 2006).”
BackgroundCannady, R., Fisher, K. R., Durant, B., Besheer, J., & Hodge, C. W. (2012) · Addiction Biology · doi:10.1111/adb.12000 · Cited by 50 · see citing works
“A prominent feature of alcoholism is excessive drinking interspersed with periods of abstinence and subsequent relapse episodes (McLellan et al. 2000; Johnson 2010).”
BackgroundFranklin, K. M., Asatryan, L., Jakowec, M. W., Trudell, J. R., Bell, R. L., & Davies, D. L. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00176 · Cited by 55 · see citing works
Agabio, R., Pani, P. P., Preti, A., Gessa, G. L., & Franconi, F. (2015) · European Addiction Research · doi:10.1159/000433579 · Cited by 45 · see citing works
Lieberman, R., Levine, E. S., Kranzler, H. R., Abreu, C., & Covault, J. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01792.x · Cited by 46 · see citing works
“Additional research is currently focusing on additional drugs for the treatment of alcohol use disorders, such as topiramate, which targets glutamate and GABAA receptors (Johnson, 2010; Miller, 2008).”
A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction
Bell, R. L., Hauser, S. R., Rodd, Z. A., Liang, T., Sari, Y., McClintick, J. N., Rahman, S., & Engleman, E. A. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.017 · Cited by 45 · see citing works
“…a particular typology predict’s the efficacy of certain pharmacotherapies (Cherpitel, Moskalewicz, & Swiatkiewicz, 2004; Dundon, Lynch, Pettinati, & Lipkin, 2004; Epstein et al., 1995; Forray & Sofuoglu, 2014; Hulse, 2012; Johnson, 2005, 2010; Johnson, Ait-Daoud, Ma, & Wang, 2003; Keating, 2013).”
InfluentialAdvances in Medications and Tailoring Treatment for Alcohol Use Disorder
Seneviratne, C. (2015) · Alcohol research · doi:10.35946/arcr.v37.1.02 · Cited by 42 · see citing works
“For example, clinical presentation can vary widely, and there is little consensus as to what constructs should be used to delineate subgroups (Johnson 2010).”
BackgroundHay, R. A., Jennings, J. H., Zitzman, D. L., Hodge, C. W., & Robinson, D. L. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12081 · Cited by 41 · see citing works
“While genetic factors are undoubtedly important to NTX efficacy (Johnson, 2010; Kimura and Higuchi, 2011), other individual differences may also be important.”
BackgroundRipley, T. L., & Stephens, D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01406.x · Cited by 38 · see citing works
“However, the effectiveness of these treatments is not universal across alcoholic patients (Egli, 2005; Heilig and Egli, 2006; Johnson, 2008; Johnson, 2010), suggesting that a single treatment for all forms of alcoholism may not be possible.”
BackgroundApplications of Pueraria lobata in treating diabetics and reducing alcohol drinking
Liu, J., Shi, Y., & Lee, D. Y. W. (2019) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2019.04.004 · Cited by 36 · see citing works
Alcohol–medical drug interactions
Johnson, B. A., & Seneviratne, C. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62619-6.00031-8 · Cited by 36 · see citing works
Self-citationCare for hospitalized patients with unhealthy alcohol use: a narrative review
Makdissi, R., & Stewart, S. (2013) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-8-11 · Cited by 34 · see citing works
“With the exception of disulfiram, medications for relapse prevention target brain receptors thought to be involved in relapse, including subsets of opioidergic, serotenergic, glutamatergic, and dopaminergic receptors [88], and complete abstinence may not be realized.”
BackgroundAlcohol abuse and disorder of granulopoiesis
Shi, X., DeLucia, A. L., Bao, J., & Ping, Z. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.001 · Cited by 34 · see citing works
“psychosocial as well as psychotherapeutic approaches to treat alcohol addiction and abuse should be the primary choice for treatment (Johnson, 2010).”
BackgroundClass I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)
Bourguet, E., Ozdarska, K., Moroy, G., Jeanblanc, J., & Naassila, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00115 · Cited by 36 · see citing works
Nicotine increases alcohol intake in adolescent male rats
Lárraga, A., Belluzzi, J. D., & Leslie, F. M. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00025 · Cited by 33 · see citing works
“Two subtypes of alcoholism have been widely recognized: TypeA, or late onset, alcoholism develops after age 25; and Type-B, or early onset, alcoholism develops before age 25 (Johnson, 2010).”
BackgroundAcosta, G., Freidman, D. P., Grant, K. A., & Hemby, S. E. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00072 · Cited by 33 · see citing works
“Previous studies in humans demonstrate clearly the potential role of iGluR modulators in the regulation of alcohol www.frontiersin.org January 2012 | Volume 2 | Article 72 | 7 regions. intake, craving, withdrawal symptoms and other outcome measures (Krupitsky et al., 2007; Johnson, 2010).”
BackgroundPharmacological management of alcohol dependence: From mono-therapy to pharmacogenetics and beyond
Caputo, F., Vignoli, T., Grignaschi, A., Cibin, M., Addolorato, G., & Bernardi, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.004 · Cited by 32 · see citing works
Lynch, W. J., Bond, C. W., Breslin, F. J., & Johnson, B. A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2253-0 · Cited by 32 · see citing works
“Both ondansetron and topiramate are believed to modulate dopaminergic signaling (Johnson 2010), and when combined, it is possible that their effects on dopamine depend on basal levels.”
Self-citationHawkins, E. J., Grossbard, J. R., Benbow, J., Nacev, V., & Kivlahan, D. R. (2012) · Military Medicine · doi:10.7205/milmed-d-12-00125 · Cited by 31 · see citing works
Behavioral and neurochemical studies in distinct animal models of ethanol's motivational effects.
Camarini, R., Pautassi, R., Méndez, M., Quadros, I. M., Souza-Formigoni, M., & Boerngen-Lacerda, R. (2010) · Current Drug Abuse Reviews · doi:10.2174/1874473711003040205 · Cited by 33 · see citing works
Asatryan, L., Yardley, M. M., Khoja, S., Trudell, J. R., Hyunh, N., Louie, S. G., Petasis, N. A., Alkana, R. L., & Davies, D. L. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001703 · Cited by 28 · see citing works
“These drugs attempt to deter alcohol intake by blocking its metabolism or by targeting the neurochemical and neuropeptide systems in the downstream cascades leading to craving and dependence (Gewiss et al., 1991; Colombo et al., 2007; Steensland et al., 2007; Johnson, 2010; Litten et al., 2012).”
Barr, C. S. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_142 · Cited by 27 · see citing works
Koller, G., Zill, P., Rujescu, D., Ridinger, M., Pogarell, O. M., Fehr, C., Wodarz, N., Bondy, B., Soyka, M., & Preuss, U. W. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01714.x · Cited by 27 · see citing works
Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder
Huynh, N., Arabian, N. M., Naito, A., Louie, S. G., Jakowec, M. W., Asatryan, L., & Davies, D. L. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.016 · Cited by 25 · see citing works
“As such, the development of effective medications to treat AUD is an important public health goal (Bouchery et al., 2011; Heilig and Egli, 2006; Johnson et al., 2007; Johnson, 2010; Steensland et al., 2007).”
Darlington, T. M., McCarthy, R. D., Cox, R. J., Miyamoto-Ditmon, J., Gallego, X., & Ehringer, M. A. (2016) · Genes Brain & Behavior · doi:10.1111/gbb.12294 · Cited by 23 · see citing works
“Understanding the neurobiological components of hedonic substitution will provide for further comprehension of the addiction process, and additional strategies for combating alcohol use disorders (AUDs).”
BackgroundInfluentialDavies, D. L., Bortolato, M., Finn, D. A., Ramaker, M. J., Barak, S., Dorit Ron, A., Liang, J., & Olsen, R. W. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01846.x · Cited by 22 · see citing works
“As such, development of effective treatments for AUDs represents an important public health goal (Bouchery et al., 2011; Heilig and Egli, 2006; Johnson, 2010; Johnson et al., 2007; Steensland et al., 2007).”
BackgroundLin, S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12163 · Cited by 22 · see citing works
Jakovljević, M., Riegler, A., Jovanović, M., Djordjević, N., Patek, K., Lesch, O., & Walter, H. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt011 · Cited by 22 · see citing works
Huynh, N., Arabian, N. M., Asatryan, L., & Davies, D. L. (2019) · Journal of Visualized Experiments · doi:10.3791/57027 · Cited by 22 · see citing works
GABAB receptor agonist only reduces ethanol drinking in light-drinking mice
Boas, G. R. V., Zamboni, C. G., Peretti, M. C., Correia, D., Rueda, A. V. L., Camarini, R., Godard, A. L. B., & Boerngen-Lacerda, R. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.04.011 · Cited by 21 · see citing works
Effects of naltrexone on alcohol drinking patterns and extinction of alcohol seeking in baboons
Kaminski, B. J., Duke, A. N., & Weerts, E. M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2688-y · Cited by 21 · see citing works
“1999) and/or decreasing motivation to drink (Johnson et al. 2004; Johnson 2010), although specific effects on urges to drink in clinical trials are unclear.”
Orrù, A., Fujani, D., Cassina, C., Conti, M., Clemente, A. D., & Cervo, L. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2672-6 · Cited by 20 · see citing works
Worley, M. J., Witkiewitz, K. A., Brown, S. A., Kivlahan, D. R., & Longabaugh, R. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12605 · Cited by 20 · see citing works
“The idea that certain medications may be more or less effective for certain types of drinkers has been proposed (Johnson, 2010).”
BackgroundMultidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease
Gitto, S., Golfieri, L., Caputo, F., Grandi, S., & Andreoné, P. (2016) · Biomolecules · doi:10.3390/biom6010011 · Cited by 20 · see citing works
“A substantial heterogeneity can be found among patients with AUD regarding age of onset, kind of drinking (continuous or binge), alcohol metabolism (worst in females) and presence or absence of associated psychiatric disorder [12].”
BackgroundThe Lesch alcoholism typology - psychiatric and psychosocial treatment approaches.
Schlaff, G., Walter, H., & Lesch, O. (2011) · Europe PMC (PubMed Central) · Cited by 20 · see citing works
Alcoholism and Substance Abuse
Warne, D. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1793-8.00065-0 · Cited by 20 · see citing works
McDowell, Y. E., Verges, A. J., & Sher, K. J. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13952 · Cited by 19 · see citing works
“In recent years, researchers have focused on identifying AUD subgroups with shared pathophysiology who may be more likely to respond to certain medications to improve medication efficacy (e.g., Johnson, 2010).”
Pharmacotherapy for alcohol use disorder.
Holt, S. R., & Tobin, D. G. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.008 · Cited by 17 · see citing works
Moore, C. F., Lycas, M. D., Bond, C. W., Johnson, B. A., & Lynch, W. J. (2014) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0035215 · Cited by 17 · see citing works
“, serotonin, glutamate, GABA), this combination has potential for a promising treatment, particularly for early onset alcoholics (Johnson, 2008; Johnson, 2010).”
Self-citationPharmacological Treatments for Alcohol Use Disorder: Considering the Role of Sex and Gender
Kirsch, D. E., Belnap, M. A., Burnette, E. M., Grodin, E. N., & Ray, L. A. (2024) · Current Addiction Reports · doi:10.1007/s40429-023-00535-x · Cited by 16 · see citing works
“To that end, a major goal is to further identify subgroups of treatment responders and possible factors that mediate pharmacotherapy treatment response [9].”
Behavioral Disinhibition With Baclofen
Soufia, M., Plaze, M., Gueguen, B., Demigneux, G., Olié, J., & Raphaël Gaillard, B. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181fb7b97 · Cited by 16 · see citing works
Yardley, M. M., Neely, M. N., Huynh, N., Asatryan, L., Louie, S. G., Alkana, R. L., & Davies, D. L. (2014) · Neuroreport · doi:10.1097/wnr.0000000000000211 · Cited by 16 · see citing works
Assessment and Treatment of Substance Use Disorders
Tinsley, J. A. (2011) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.9.1.foc3 · Cited by 15 · see citing works
Long-term Management of Alcoholic Liver Disease
Woo, G. A., & O’Brien, C. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.08.007 · Cited by 14 · see citing works
O’Connor, P. G. (2012) · Goldman's Cecil Medicine · doi:10.1016/b978-1-4377-1604-7.00032-4 · Cited by 13 · see citing works
Echeverry‐Alzate, V., Tuda-Arízcun, M., Bühler, K., Santos, Á., Giné, E., Olmos, P., Gorriti, M. Á., Huertas, E., de Fonseca, F. R., & López‐Moreno, J. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.010 · Cited by 12 · see citing works
“), two clinically approved medications to treat binge ethanol consumption, ethanol abuse and dependence and to prevent relapse (Fuller and Gordis, 2001; Johnson, 2010; Mason, 2003; O'Brien et al., 1996; Spanagel and Zieglgänsberger, 1997).”
Duncan, P. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781139025515.013 · Cited by 12 · see citing works
Alcohol and UK recreational divers: consumption and attitudes.
Dowse, M. S. L., Cridge, C., Shaw, S. R., & Smerdon, G. R. (2012) · PubMed · Cited by 11 · see citing works
Höfer, P., Syeda, B., Bergler-Klein, J. K., Friedrich, F., Lesch, O., Vyssoki, B., Binder, T. M., & Walter, H. (2011) · Alcohol and Alcoholism · doi:10.1093/alcalc/agr027 · Cited by 10 · see citing works
“It is evident that different subgroups, even if the subtype classification of alcoholism remains controversial, need different therapy approaches, concerning medical withdrawal and relapse prevention treatment (Johnson, 2010; Lesch et al., 2011).”
BackgroundZhao, Y., Zheng, Z., & Castellanos, F. X. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.10.040 · Cited by 10 · see citing works
“To reduce deleterious health impacts and the associated economic loss, mechanistic understanding of AUD pathogenesis is required for developing more effective strategies for AUD prevention and treatment (Johnson, 2010; Litten et al., 2015; Reilly et al., 2014; Zahr et al., 2011).”
BackgroundJohnson, B. A., Alho, H., Addolorato, G., Lesch, O. M., Chick, J., Liu, L., & Schuyler, V. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.06.001 · Cited by 9 · see citing works
Self-citationDisulfiram: An Anticraving Substance?
Müller, C. A., & Banas, R. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10070943 · Cited by 10 · see citing works
Flanagan, J. C., Joseph, J. E., Nietert, P. J., Back, S. E., & McCrady, B. S. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.05.002 · Cited by 8 · see citing works
Johnson, B. A., Messing, R. O., Charness, M. E., Crabbe, J. C., Goldman, M. S., Harris, R. A., Kranzler, H. R., Mitchell, M. C., Nixon, S. J., Riley, E. P., et al. (2011) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01493.x · Cited by 7 · see citing works
“…and alcohol activate similar reward pathways and that cannabinoid receptors may be associated with the reinforcing effects of alcohol (SUAA Working Group, 2010), it has not been proven that targeting cannabinoid signaling is an efficacious strategy for treating alcohol dependence (Johnson, 2010b).”
Self-citationLee, T. H., Szabo, S. T., Fowler, J. C., Mannelli, P., Mangum, O. B., Beyer, W. F., Patkar, A. A., & Wetsel, W. C. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.01.021 · Cited by 6 · see citing works
“Ondansetron has also shown to be useful in the treatment of alcohol withdrawal (Johnson, 2010).”
Shedler, J., Beck, A. T., Fonagy, P., Gabbard, G. O., Kernberg, O. F., Michels, R., & Westen, D. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10101466r · Cited by 6 · see citing works
Duncan, P. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781139025515 · Cited by 6 · see citing works
Treatments for Alcohol Dependence: Rethinking the Role of Comorbidity and Clinical Subtypes
Patkar, A. A., & Li, T. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10030309 · Cited by 5 · see citing works
Bell, R. L., Franklin, K. M., Hauser, S. R., & Zhou, F. (2012) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912800673155 · Cited by 5 · see citing works
“profile [131–135].”
Rolland, B., Laprévote, V., Geoffroy, P. A., Guardia, D., Schwan, R., & Cottencin, O. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.02.038 · Cited by 4 · see citing works
“boire (traitements anticraving), devra également s’intégrer à une médecine personnalisée du patient alcoolodépendant [29].”
Alcoholism: The Self-Reinforcing Feedback Loop
Dorrian, J. (2012) · InTech eBooks · doi:10.5772/31626 · Cited by 4 · see citing works
Mangot, A. G., Murthy, V., & Jamale, S. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.05.002 · Cited by 4 · see citing works
Health Psychology in Australia
Dorrian, J., Thorsteinsson, E., Benedetto, M. D., Lane‐Krebs, K., Day, M. A., Hutchinson, A. D., & Sherman, K. A. (2017) · Cambridge University Press eBooks · doi:10.1017/9781316779156 · Cited by 4 · see citing works
Alcoholism and Substance Abuse
Warne, D. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00083-9 · Cited by 4 · see citing works
Bradley, K. A., & Williams, E. C. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1441-7 · Cited by 3 · see citing works
Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics?
Coppola, M., & Mondola, R. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.03.030 · Cited by 3 · see citing works
“sants [30–34].”
Asadollahi, A., Kaveh, M. H., Saberi, L. F., Karimi, M., & Ahmad, N. B. (2023) · Journal of Cross-Cultural Gerontology · doi:10.1007/s10823-023-09470-w · Cited by 3 · see citing works
Horsman, E. N. (2014) · OpenSIUC (Southern Illinois University Carbondale) · Cited by 3 · see citing works
A Proper Name for Chronic Tic Disorder
Ramírez‐Bermúdez, J., & Pérez-Rincón, H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10040477 · Cited by 2 · see citing works
Reid, L. D. (2015) · Cited by 2 · see citing works
Substance abuse and dependence
Waller, D. G., & Sampson, A. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-7167-6.00054-3 · Cited by 2 · see citing works
A Primer on College Student Substance Use Disorders Screening, Assessment, and Treatment Planning
Cooper, S. E. (2017) · Journal of College Student Psychotherapy · doi:10.1080/87568225.2017.1343107 · Cited by 2 · see citing works
“Johnson (2010) reported that one quarter of college students indicated that their drinking had contributed to academic problems like missing classes, poor grades, or missing assignments.”
BackgroundSharma, R., Sahota, P. K., & Thakkar, M. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816430-3.00009-9 · Cited by 2 · see citing works
Juřica, J., Zendulka, O., Trubač, R., & Šulcová, A. (2011) · Cited by 1 · see citing works
ANXIOLYTIC PROFILE OF 5-HT3 ANTAGONIST ONDANSETRON AND ITS CLINICAL CORRELATION
Kumar, A. A., Sravani, P., & Priya, V., V (2014) · International Journal of Pharma and Bio Sciences · Cited by 1 · see citing works
Molecular Mechanisms of Drug Abuse, Dependency and Craving
Wilcox, R. E. (2016) · Journal of Addiction and Dependence · doi:10.15436/2471-061x.16.006 · Cited by 1 · see citing works
Promises and risks for participants in studies of genetic risk for alcohol or drug dependence
Fisher, C. E., Hasin, D. S., & Appelbaum, P. S. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139058971.004 · Cited by 1 · see citing works
- Authors
- Johnson, B. A.
- Affiliations
- University of Virginia (US)
- Corresponding author
- Johnson, Bankole A.
- ORCID
- Johnson, Bankole A.
- Venue
- American Journal of Psychiatry
- Published
- 2010-06-01
- Volume
- 167
- Issue
- 6
- Pages
- 630-639
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC2939449
- OpenAlex
- W2142440641
- Cited by
- 151
- References
- 72
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 4 · 2021: 2 · 2020: 23 · 2019: 11 · 2018: 3 · 2017: 10 · 2016: 8 · 2015: 10 · 2014: 10 · 2013: 11 · 2012: 31
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (R01AA010522, R01AA013964, R01AA014628, U10AA011776, R01AA012964)
- National Center for Research Resources (M01RR000847, M01-RR 00847)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholism, pharmacological treatment of alcoholism, dopaminergic system, ondansetron, naltrexone, topiramate, baclofen, early-onset alcoholism, late-onset alcoholism, binge drinking, pharmacogenetics, brief behavioral intervention, abstinence
- MeSH terms
- Topiramate, Adult, Aged, Alcohol Deterrents, Alcoholism, Baclofen, Chronic Disease, Depressive Disorder, Female, Fructose, Humans, Hypothalamo-Hypophyseal System, Limbic System, Male, Naltrexone, Pituitary-Adrenal System, Ondansetron, Prefrontal Cortex, Receptors, Dopamine D2, Receptors, GABA, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review